96847-53-9

Basic information

• Product Name: (1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one
• Synonyms: Milnacipran Hydrochloride Impurity 2;cis-(-)-1-Phenyl-2-oxo-3-oxabicyclo[3.1.0]hexane;(1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-oneacid;3-Oxabicyclo[3.1.0]hexan-2-one, 1-phenyl-, (1S,5R)-;cis-(-)-1-Phenyl-2-oxo-3-oxabicyclo[3.1.0]hexane 98%;(1S,5R)-1-phenyl-2-oxo-3-oxa bicyclo[3.1.0]hexane (96847-53-9)
• CAS NO: 96847-53-9
• Molecular Formula: C₁₁H₁₀O₂
• Molecular Weight: 174.1959
• Mol File: 96847-53-9.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 340.0±21.0 °C(Predicted)
• Appearance: /
• Density: 1.300±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one(96847-53-9)
• EPA Substance Registry System: (1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one(96847-53-9)

Safety Data

• Hazardous Substances Data: 96847-53-9(Hazardous Substances Data)

Usage

General Description

"(1S,5R)-1-Phenyl-3-oxabicyclo[3.1.0]hexan-2-one" is a chemical compound with a complex structure that includes a cyclohexane derivative, with various substitutions. One of these substitutions is an oxygen atom, which is incorporated into the structure to create an "oxabicyclo" compound. This chemical also includes a carbonyl group (C=O) at carbon number 2, leading to the "hexan-2-one" in its name. The phenyl group present refers to a ring of six carbon atoms (a benzene ring) attached to the compound. Its molecular structure is specified by the notation (1S,5R), which refers to the specific configuration and orientation of these groups around the chiral centers in the chemical compound. Its detailed properties would depend on its exact context and its interactions with other compounds.

Upstream product

• 51594-55-9 (R)-(-)-epichlorohydrin 
• 140-29-4 phenylacetonitrile 
• 60788-55-8 2-Hydroxymethyl-1-phenyl-cyclopropanecarbonitrile 
• 63106-93-4 1-phenyl-3-oxa-bicyclo[3.1.0]hexan-2-one 
• 145193-16-4 allyl α-phenyl-α-diazoacetate 
• 96847-49-3 (1S,2R)-2-(hydroxymethyl)-1-phenyl-N-[(1R)-1-phenyl-ethyl]cyclopropanecarboxamide 
• 67843-74-7 (S)-epichlorohydrin 
• 106-89-8 epichlorohydrin 
• 1797-74-6 allyl phenylacetate 
• 103-80-0 phenylacetyl chloride 
• 22613-99-6 cis-2-Hydroxymethyl-1-phenyl-cyclopropan-1-carbonsaeure 

Downstream Products

• 172015-99-5 (1 S,2 R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide 
• 69160-63-0 (1S,2R)-2-(bromomethyl)-1-phenylcyclopropanecarboxylic acid 
• 459143-35-2 ((1S,2R)-2-Hydroxymethyl-1-phenyl-cyclopropyl)-pyrrolidin-1-yl-methanone 
• 459143-36-3 ((1S,2R)-2-Hydroxymethyl-1-phenyl-cyclopropyl)-piperidin-1-yl-methanone 
• 459143-33-0 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N,N-di-isobutylcyclopropanecarboxamide 
• 69160-65-2 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N-ethylcyclopropanecarboxamide 
• 459143-31-8 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N,N-dipropylcyclopropanecarboxamide 
• 459143-32-9 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N,N-dibutylcyclopropanecarboxamide 
• 459143-30-7 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N,N-dimethylcyclopropanecarboxamide 
• 459143-34-1 (1S,2R)-1-phenyl-2-(hydroxymethyl)-N,N-dibenzylcyclopropanecarboxamide 
• 763126-74-5 (1R,2S)-1,2-di(hydroxymethyl)-2-phenylcyclopropane 
• 1001017-62-4 (1S,2R)-2-(bromomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 
• 96847-54-0 (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide 
• 174848-98-7 (1S,2R)-2-(azidomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF LEVOMILNACIPRAN

The present invention discloses cost-effective, industrially efficient and safe process synthesis of levomilnacipran that is devoid of 1-phenyl-1- diethylaminocarbonyl-2- chloromethylcyclopropane.

(+)-Methyl (1 R, 2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] derivatives as potent and selective sigma receptor ligands: Stereochemistry and pharmacological properties

Methoxycarbonyl-1-phenyl-2-cyclopropylmethyl based derivatives cis-(+)-1a [cis-(+)-MR200], cis-(-)-1a [cis-(-)-MR201], and trans-(±)-1a [trans-(±)-MR204], have been identified as new potent sigma (σ) receptor ligands. In the present paper, novel enantiomerically pure analogues were synthesized and optimized for their σ receptor affinity and selectivity. Docking studies rationalized the results obtained in the radioligand binding assay. Absolute stereochemistry was unequivocally established by X-ray analysis of precursor trans-(+)-5a as camphorsulfonyl derivative 9. The most promising compound, trans-(+)-1d, showed remarkable selectivity over a panel of more than 15 receptors as well as good chemical and enzymatic stability in human plasma. An in vivo evaluation evidenced that trans-(+)-1d, in contrast to trans-(-)-1d, cis-(+)-1d, or cis-(-)-1d, which behave as σ1 antagonists, exhibited a σ1 agonist profile. These data clearly demonstrated that compound trans-(+)-1d, due to its σ1 agonist activity and favorable receptor selectivity and stability, provided an useful tool for the study of σ1 receptors.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.